<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859231</url>
  </required_header>
  <id_info>
    <org_study_id>6042</org_study_id>
    <nct_id>NCT04859231</nct_id>
  </id_info>
  <brief_title>Nutritive Effects of Cow's Milk-Based Formulas Through 18 Months of Age</brief_title>
  <official_title>Nutritive Effects of Cow's Milk-Based Formulas Through 18 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mead Johnson Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mead Johnson Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will assess nutritive effects on brain myelination in infants assigned to&#xD;
      receive one of two study formula or mother's own breast milk through 18 month's of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">May 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 7, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MR Imaging</measure>
    <time_frame>365 days of age</time_frame>
    <description>Brain Imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MR Imaging</measure>
    <time_frame>180 and 545 days of age</time_frame>
    <description>Brain Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gap Overlap Paradigm</measure>
    <time_frame>180 and 365 days of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Expectation Paradigm</measure>
    <time_frame>180 and 365 days of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A-not-B Task</measure>
    <time_frame>365 and 545 days of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bayley Scales of Infant and Toddler Development, Third Edition</measure>
    <time_frame>365 and 545 days of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>180, 365 and 545 days of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length</measure>
    <time_frame>180, 365 and 545 days of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head Circumference</measure>
    <time_frame>180, 365 and 545 days of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recall of Study Feeding</measure>
    <time_frame>180, 275 (HM Reference group only), 365 and 545 days of age</time_frame>
    <description>Feeding Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Microbiome Composition</measure>
    <time_frame>180, 365 and 545 days of age</time_frame>
    <description>Sequence analysis using QIIME 2.0 (quantitative insights into microbial ecology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically confirmed Adverse Events</measure>
    <time_frame>Through study completion, on average 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Nutritive Effects on Brain Myelination</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mother's-own Breast Milk</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Cow's milk-based formula</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Investigational</intervention_name>
    <description>Cow's milk-based formula with added source of enriched whey protein</description>
    <arm_group_label>Investigational</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton birth&#xD;
&#xD;
          -  Gestational age of 37-42 weeks (36 weeks and six days is considered 36 weeks&#xD;
             gestational age)&#xD;
&#xD;
          -  Birth weight of 2500 g (5 lbs 8 oz) or more&#xD;
&#xD;
          -  Parent(s) or legal guardian agrees not to enroll infant in another interventional&#xD;
             clinical study while participating in this study&#xD;
&#xD;
          -  Signed informed consent obtained for infant's participation in the study&#xD;
&#xD;
          -  Signed authorization obtained to use and/or disclose Protected Health Information for&#xD;
             infant from birth through 18 months of age&#xD;
&#xD;
        Infants receiving formula:&#xD;
&#xD;
          -  3 to 60 days of age at randomization, inclusive (day of birth is considered day 0)&#xD;
&#xD;
          -  Exclusively receiving infant formula for at least 72 hours prior to randomization&#xD;
&#xD;
          -  Parent(s) or legal guardian has full intention to exclusively feed study formula&#xD;
             during the study period&#xD;
&#xD;
        Infants receiving human milk:&#xD;
&#xD;
          -  150-180 days of age at registration, inclusive (day of birth is considered day 0)&#xD;
&#xD;
          -  Mother has intention to predominately provide mother's own breast milk through at&#xD;
             least 10 months of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  First degree relative with known autism, intellectual disability, schizophrenia, or&#xD;
             bipolar disorder or an inherited disorder of myelination&#xD;
&#xD;
          -  Major pre- and/or perinatal issues (such as maternal pre-eclampsia, placental&#xD;
             abruption, maternal alcohol or illicit drug use during pregnancy)&#xD;
&#xD;
          -  Major delivery complications (such as neonatal hypoxia or neonatal illness requiring a&#xD;
             greater than 2-day NICU stay)&#xD;
&#xD;
          -  Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiency&#xD;
             such as combined immunodeficiencies, DiGeorge syndrome, Wiskott-Aldrich syndrome,&#xD;
             severe congenital neutropenia and secondary immunodeficiencies linked to HIV&#xD;
             infection, Down syndrome or others)&#xD;
&#xD;
          -  5 minute APGAR &lt; 7&#xD;
&#xD;
          -  Infant was born large for gestational age (LGA) (as confirmed by the hospital birth&#xD;
             records) from mother who was diabetic at childbirth&#xD;
&#xD;
          -  Infant has been identified with inadequate weight gain or failure to thrive by a&#xD;
             health care professional (HCP)&#xD;
&#xD;
          -  History of underlying metabolic or chronic disease; congenital malformation; or any&#xD;
             other condition which, in the opinion of the Investigator, is likely to interfere&#xD;
             with: the ability of the infant to ingest food, the normal growth and development of&#xD;
             the infant, or the evaluation of the infant&#xD;
&#xD;
          -  Parent(s) or legal guardian unable to speak English at a level to provide informed&#xD;
             consent&#xD;
&#xD;
        Infants receiving formula:&#xD;
&#xD;
        • Evidence of feeding difficulties or history of formula intolerance, such as vomiting or&#xD;
        poor intake at time of randomization&#xD;
&#xD;
        Infants receiving human milk:&#xD;
&#xD;
        • Use of infant formula and/or donor milk more than three times per week prior to&#xD;
        registration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>180 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashlee Kirchoff</last_name>
    <phone>812-429-7997</phone>
    <email>ashlee.kirchoff@rb.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven S Wu, MD</last_name>
    <phone>812-429 7564</phone>
    <email>steven.wu2@rb.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Baluyot</last_name>
      <phone>919-843-5420</phone>
      <email>kristine_baluyot@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Jimenez</last_name>
      <phone>919-843-4640</phone>
      <email>jordan_jimenez@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Weili Lin, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Hernandez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

